Rosemarie Martin to Buprenorphine
This is a "connection" page, showing publications Rosemarie Martin has written about Buprenorphine.
Connection Strength
1.701
-
Martin RA, Berk J, Rich JD, Kang A, Fritsche J, Clarke JG. Use of long-acting injectable buprenorphine in the correctional setting. J Subst Abuse Treat. 2022 11; 142:108851.
Score: 0.613
-
Stahler GJ, Mennis J, Stein LAR, Belenko S, Rohsenow DJ, Grunwald HE, Brinkley-Rubinstein L, Martin RA. Treatment outcomes associated with medications for opioid use disorder (MOUD) among criminal justice-referred admissions to residential treatment in the U.S., 2015-2018. Drug Alcohol Depend. 2022 07 01; 236:109498.
Score: 0.604
-
Bailey A, DaCunha A, Napoleon SC, Kang AW, Kemo M, Martin RA. Provision of medications to treat opioid use disorder via a mobile health unit: A scoping review. J Subst Use Addict Treat. 2024 Sep; 164:209431.
Score: 0.174
-
Kaplowitz E, Truong AQ, Berk J, Martin RA, Clarke JG, Wieck M, Rich J, Brinkley-Rubinstein L. Treatment preference for opioid use disorder among people who are incarcerated. J Subst Abuse Treat. 2022 06; 137:108690.
Score: 0.147
-
Macmadu A, Adams JW, Bessey SE, Brinkley-Rubinstein L, Martin RA, Clarke JG, Green TC, Rich JD, Marshall BDL. Optimizing the impact of medications for opioid use disorder at release from prison and jail settings: A microsimulation modeling study. Int J Drug Policy. 2021 05; 91:102841.
Score: 0.133
-
Clarke JG, Martin RA, Gresko SA, Rich JD. The First Comprehensive Program for Opioid Use Disorder in a US Statewide Correctional System. Am J Public Health. 2018 10; 108(10):1323-1325.
Score: 0.029